<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168130">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01851499</url>
  </required_header>
  <id_info>
    <org_study_id>Normast-2013</org_study_id>
    <nct_id>NCT01851499</nct_id>
  </id_info>
  <brief_title>Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain</brief_title>
  <official_title>Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain: a Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Pain Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spinal Cord Injury Centre of Western Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Spinal Cord Injuries, Glostrup Hospital, Hornbaek, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epitech Group SRL, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Pain Research Center</source>
  <oversight_info>
    <authority>Denmark: The National Committee on Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blinded, placebo-controlled, parallel group study of ultramicronized PEA
      (Normast)600 mg x 2 daily or corresponding placebo with a week of baseline period followed
      by 1 x 12 weeks treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Randomized, double-blinded, placebo-controlled, parallel, multi-center study
      of ultramicronized PEA (Normast)with a week of baseline period followed by 1 x 12 weeks
      treatment period.

      Methodology: Given Normast 600mg x 2 daily or corresponding placebo and kept on that dose
      for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in mean pain intensity on a 0-10 numerical rating scale from baseline week to last week of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spasticity/spasms and sleep disturbance, change in mean score from baseline to last week of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Tardieu and clonus over ankle joints</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity and spasms on a 0-10 NRS</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life S-TOPS</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Change</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief of overall pain and at-and below level pain</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>allodynia(touch and cold)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain symptoms evaluated by NPSI</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain impact on activities, sleep and mood</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on unpleasantness</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>escape medication</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety(GAD-10)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression(MDI)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NNT for 33% and 50% pain reduction</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined spasticity and pain score (CPSS)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of responders (33% pain reduction) in those with and without allodynia/hyperalgesia and those with different pain symptoms (NPSI)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Blindness is assessed by asking the patients and treating physician which treatment they believed they recieved and the reason for this</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse events and number, type and severity of adverse events.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adverse events are assessed using open-ended questions both during and after treatment period.
SAE reporting will be performed according to GCP and regulatory requirements.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Ultramicronized PEA (Normast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normast is ultramicronized Palmitoylethanolamide (PEA) classified as &quot;Dietary foods for special medical purposes&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microgranules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ultramicronized PEA (Normast)</intervention_name>
    <arm_group_label>Ultramicronized PEA (Normast)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or more with at- and/or below-level neuropathic pain for at
             least 3 months due to trauma or disease of the spinal cord or cauda equina (of at
             least 6 months old) with a mean pain intensity from 4 to 9 on a 0-10 point numeric
             rating scale (NRS) during a one-week baseline period will be eligible for the study

        Exclusion Criteria:

          -  known concomitant severe cerebral damage, terminal illness, planned surgery,
             pregnancy or lactation, alcohol or substance abuse, hypersensitivity to PEA or
             carrier, and psychiatric disease except depression.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven R. Andresen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spinal Cord Injury Centre of Western Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven R. Andresen, MD</last_name>
    <phone>+45 7844 6156</phone>
    <email>sven.robert.andresen@midt.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nanna B. Finnerup, MD</last_name>
    <phone>+45 7846 3455</phone>
    <email>finnerup@ki.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Spinal Cord Injuries</name>
      <address>
        <city>Hornbaek</city>
        <zip>3100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fin Biering-Soerensen, Professor</last_name>
      <phone>+45 3545 1950</phone>
      <email>fin.biering-soerensen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jette Bing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fin Biering-Soerensen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spinal Cord Injury Centre of Western Denmark</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven R. Andresen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sven R. Andresen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inger L. Johannesen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rikke M. Hansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen M. Hagen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 9, 2013</lastchanged_date>
  <firstreceived_date>May 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic pain following spinal cord injury</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
